Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin

Delhorme, Jean-Baptiste; Séverac, François; Sgarbură, Olivia; Abba, J.; Abboud, Karine; Alyami, Mohammad; Arvieux, C.; Avérous, Gerlinde; Bakrin, Naoual; Balagué, Gisèle; Barrau, Vincent; Rejeb, Houda Ben; Jm, Bereder; Berton-Rigaud, Isabelle; Bibeau, Frédéric; Bonnefoy, Isabelle; Bouzard, D.; Bricault, Ivan; Brigand, Cécile; Carrère, Sébastien; Chaisemartin, Cécile de; Chassang, Madleen; Chevallier, A; Courvoisier, Thomas; Dartigues, Peggy; Dohan, Anthony; Dubreuil, Julien; Dumont, Frédéric; Eveno, Clarisse; Faruch-Bilfeld, Marie; Ferron, Gwénaël; Fontaine, Juliette; Fournier, Laure; Gagnière, Johan; Geffroy, D.; Ghouti, Laurent; Gilly, F. N.; Gladieff, Laurence; Gléhen, Olivier; Goèré, Diane; Guibal, Aymeric; Guilloit, J-M; Guyon, Frédéric; Heyd, Bruno; Hoeffel, Christine; Hordonneau, Constance; Isaac, Sylvie; Jourdan-Enfer, Peggy; Kaci, Rachid; Kianmanesh, Réza; Labbé-Devilliers, C.; Lacroix, Joëlle; Lelong, Bernard; Leroux-Broussier, A.; Lherm, Yoann; Dico, Réa Lo; Lorimier, G.; Malhaire, Caroline; Marchal, Frédéric; Mariani, Pascale; Mathiotte, E.; Méeus, Pierre; Mery-Lamarche, Eliane; Msika, Simon; Nadeau, C.; Ortega-Deballon, P.; Passot, Guillaume; Pellet, Olivier; Peyrat, Patrice; Pezet, Denis; Pirrò, N.; Pocard, Marc; Poizat, Flora; Porcheron, J.; Poulet, A.; Quénet, François; Rat, P.; Rousselot, Pierre; Rousset, Pascal; Senellart, Hélène; Serrano, Martine; Servois, Vincent; Sgabura, Olivia; Skanjeti, Andrea; Svrcek, Magali; Tétreau, Raphaël; Thibaudeau, Emilie; Touchefeu, Yann; Tuech, J.‐J.; Valmary‐Degano, Séverine; Vaudoyer, Delphine; Velasco, Stéphane; Verriele-Beurrier, Véronique; Villeneuve, Laurent; Wernert, Romuald; Zinzindohoué, Franck

doi:10.1002/bjs.10716

Cited by 45 publications

(26 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports did not find any difference in survival between appendix-derived PMP and non-appendix-derived PMP (23,24). However, the OS of non-appendix-derived PMP was lower than that of appendix-derived PMP in the present study.…”

Section: Discussioncontrasting

confidence: 84%

Clinicopathological Characteristics and Prognostic Prediction in Pseudomyxoma Peritonei Originating From Mucinous Ovarian Cancer

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo describe the clinicopathological characteristics of mucinous ovarian cancer (MOC)-derived pseudomyxoma peritonei (PMP) and identify prognostic factors for survival.MethodsMedical records from patients with MOC-derived PMP who attended the Aerospace Center Hospital, Beijing, China between January 2009, and December 2019 were retrospectively reviewed. Survival analysis was performed with the Kaplan-Meier method, the log-rank test, and a Cox proportional hazards model.ResultsCytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for PMP originating from MOC were performed on 22 patients, who had a median age of 52 years at the time of surgery. At the last follow-up in June 2020, 9 (41%) patients were still alive. Median OS was 12 months (range, 1 to 102 months), and the 2-, 3-, and 5-year survival rates were 23, 9, and 5%, respectively.ConclusionHistopathologic subtype and PCI may be applied as predictors of prognosis in patients with MOC-derived PMP. Patients with high-grade disease could benefit from completeness of cytoreduction (CCR) 0/1.

show abstract

Section: Discussioncontrasting

confidence: 84%

Clinicopathological Characteristics and Prognostic Prediction in Pseudomyxoma Peritonei Originating From Mucinous Ovarian Cancer

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The best therapeutic approach should always be radical surgery, followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy [ 5 , 7 ]. Since most PMPs, appears from the appendix it should always be removed [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

Abdominal hernia and the unexpected final diagnosis

Cevallos

Moyón

Pozo³

et al. 2018

Journal of Surgical Case Reports

View full text Add to dashboard Cite

Mucinous neoplasm of the appendix are rare entities, among these, mucinous cystadenomas contribute to 31–34%. Cystadenomas often produce extensive dilatation of the appendix with epithelial atypia. Spontaneous perforation often occurs in 20%, leading to mucin distribution throughout the peritoneal cavity. Half of the patients are completely asymptomatic and are detected as an incidental diagnosis, others symptoms include a palpable mass, hernias, weight loss, peritonism or even intestinal obstruction. We present a case of a 71-year-old female, she presented with a palpable mass in the upper abdomen. A ventral hernia was the most likely diagnosis and hernioplasty was planned. At surgery, a mucinous mass was discovered and mucous material was found free en the peritoneal cavity. Also, a perforated appendix and a mass in the cecum was found. Patient underwent full recovery. Pathology reported pseudomyxoma peritonei as the final diagnosis.

show abstract

“…To date, HIPEC regimen-related studies have been mostly single-or multicenter large-sample analyses [17,19,[34][35][36][37][38][39][40][41][42][43][44][45][46][47][48]. In 2018, Levine et al published the first multicenter randomized controlled trial on appendixderived PMP.…”

Section: Controversies On Hipec Regimensmentioning

confidence: 99%

Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines

Lin

et al. 2021

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background Pseudomyxoma peritonei (PMP) is a clinical malignant syndrome mainly originating from the appendix, with an incidence of 2–4 per million people. As a rare disease, an early and accurate diagnosis of PMP is difficult. It was not until the 1980s that the systematic study of this disease was started. Main body As a result of clinical and basic research progress over the last 4 decades, a comprehensive strategy based on cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) has been established and proved to be an effective treatment for PMP. Currently, CRS + HIPEC was recommended as the standard treatment for PMP worldwide. There are several consensuses on PMP management, playing an important role in the standardization of CRS + HIPEC. However, controversies exist among consensuses published worldwide. A systematic evaluation of PMP consensuses helps not only to standardize PMP treatment but also to identify existing controversies and point to possible solutions in the future. The controversy underlying the consensus and vice versa promotes the continuous refinement and updating of consensuses and continue to improve PMP management through a gradual and continuous process. In this traditional narrative review, we systemically evaluated the consensuses published by major national and international academic organizations, aiming to get a timely update on the treatment strategies of CRS + HIPEC on PMP. Conclusion Currently, consensuses have been reached on the following aspects: pathological classification, terminology, preoperative evaluation, eligibility for surgical treatment, maximal tumor debulking, CRS technical details, and severe adverse event classification system. However, controversies still exist regarding the HIPEC regimen, systemic chemotherapy, and early postoperative intraperitoneal chemotherapy.

show abstract

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin

Abstract: Overall and disease-free survival following treatment with CCRS and HIPEC is similar in patients with pseudomyxoma peritonei of appendicular or extra-appendicular origin.

Cited by 45 publications

References 45 publications

Clinicopathological Characteristics and Prognostic Prediction in Pseudomyxoma Peritonei Originating From Mucinous Ovarian Cancer

Clinicopathological Characteristics and Prognostic Prediction in Pseudomyxoma Peritonei Originating From Mucinous Ovarian Cancer

Abdominal hernia and the unexpected final diagnosis

Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines

Contact Info

Product

Resources

About